AzTrials
AzTrials

Mendelian DisordersNCT02021734

Genetics of Mendelian Diseases in Qatar

An observational study of Mendelian Disorders, run by Weill Medical College of Cornell University at 1 site in Qatar.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Mendelian Disorders
How many people
400 participants
Where
1 siteQatar
Study dates
19 Nov 2012to Feb 2025
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: physicians and by thorough review of the literature to establish that the disease is indeed Mendelian and with unknown gene.

Who may be able to join

  • All included individuals must provide informed consent
  • All genetic disorders are included
  • All ethnic backgrounds are accepted
  • Disease must be genetic with no evident environmental cause
  • Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:
  • Multiple affected family members (at least first degree relative with disease)
Show all 11Show fewer
  • History of consanguinity
  • Severe disease in newborn in the absence of family history
  • Sydromic disease in single individuals
  • Congenital abnormality affecting major organ system(s)
  • Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)

Who cannot join

  • Individuals who do no consent to be included
  • Mendelian disease for which a gene mutation has already been identified
  • Individuals for which a molecular diagnosis has already been established by alternative method
  • Disease for which an environmental factor is most likely the cause
  • Disease for which late age of onset rule out Mendelian transmission
  • Common diseases for which late age of onset rule out Mendelian transmission

Trial locations and contacts

1 site in 1 country.

Qatar1 site
  • Hamad Medical Corporation

    Doha

Other trials in Qatar

About this study

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools.

Read the detailed description

There are certain categories of diseases which are more prevalent in the Arab world due to increased rates of consanguinity in relatively isolated populations. The goal is to discover these mutations by using next-generation human genetics tools. These include high-throughput sequencing and genotyping along with the necessary bioinformatics analyses that will lead to the discovery of the causes of most inherited diseases in the region.The secondary objective will be to build a comprehensive catalogue of genetic variation in the Arab world. This will include all detected mutations, not only the subset that are causing disease (from primary objective), but also known trait-altering mutations as well as general diversity on the DNA level among human populations of this region. This catalogue can become a widely useful resource for many projects down the road, as it relies on anonymizing individual samples and instead displaying data in aggregate as the cohorts of collected samples grow over the years.

The study will include all genetic disorders from all ethnic backgrounds but Mendelian disease for which a gene mutation has already been identified will be excluded.

Evidence of Mendelian Transmission determined by fulfilling one of the following criteria:

Multiple affected family members (at least first degree relative with disease) History of consanguinity Severe disease in newborn in the absence of family history Sydromic disease in single individuals Congenital abnormality affecting major organ system(s) Mendelianized extremes of common disease (eg sever familial diabetes/ obesity/ hypertension)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Next generation sequencing

    Use next generation sequencing to detect novel disease causing mutations

    Measured: 1 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Dec 2013 (estimated)
  2. Study start19 Nov 2012
  3. Primary completionJun 2022
  4. Study completionFeb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Family based
Time perspective
Prospective
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02021734
Sponsor's protocol ID
13-00065 [JIRB]
Other IDs
12217/12
Status last verified
Nov 2025
First submitted
22 Nov 2013
Last updated
17 Nov 2025
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in